EBR Systems (ASX:EBR) said that its WiSE cardiac resynchronization therapy system was implanted in the first commercial patients in the US, following approval from the Food and Drug Administration, according to a Friday Australian bourse filing.
Reimbursement add-on payments for both inpatients and outpatients are expected to begin in October, the filing said.
The initiation of its limited market release is also expected in October, running into 2026, aimed at developing clinician advocacy and facilitating wider adoption.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。